1 / 35

Squamous Cell Carcinoma

Squamous Cell Carcinoma. Incidence. 2 nd most common skin cancer Behind BCC, accounting for 20% skin cancers Due to propensity to metastasise, makes them responsible for majority of NMSC deaths. Pathogenesis. UV Incidence doubles with 8-10 degrees decrease in latitude

ceri
Download Presentation

Squamous Cell Carcinoma

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Squamous Cell Carcinoma

  2. Incidence • 2nd most common skin cancer • Behind BCC, accounting for 20% skin cancers • Due to propensity to metastasise, makes them responsible for majority of NMSC deaths

  3. Pathogenesis • UV • Incidence doubles with 8-10 degrees decrease in latitude • Induces formation of pyrimidine dimers resulting in DNA point mutations • Causes mutations in p53 tumour suppressor gene

  4. Skin pigmentation • Age • Primary dermatoses – xeroderma pigmentosa, oculocutaneous albinism

  5. Immunosuppression – due to immunosuppressive drugs, UVR, viral infection esp HPV • Reversed ratio of BCC:SCC, SCC being 3x more common in transplant patients • Higher rates – cumulative risk of SCC/ BCC in heart transplant recipient is 3% at one year, 21% at 5 years, 35% at 10 years

  6. Histological subtypes • Pleomorphic • Adenoid/Acantholytic • Simplex • Small cell • Verrucous • Keratoacanthoma • Actinic keratosis • Bowenoid/Erythoplasia of Queyrat

  7. Simplex • Majority of SCCs • Atypical keratinocytes develop within epidermis and invade the dermis • Tumour cells are enlarged, hyperchromatic, variably pleomorphic nuclei, prominent mitotic activity • Keratin pearls

  8. Actinic Keratosis • Also SCC in situ, micro invasive SCC, as there is considerable overlap in the histology • Atypical keratinocytes that have not breached the dermal barrier • SCCIS is typically full thickness keratinocyte atypia

  9. Rate of malignant transformation is 0.1% per lesion per year • About 16% will eventually transform • Can progress to other skin cancers such as sebaceous carcinoma

  10. Pleomorphic • AKA spindle / sarcomatoid, RARE • Associated with previous trauma or RTX • Most commonly found on face or sun exposed areas of elderly • Commonly ulcerate, but may present as an exophytic mass

  11. Microscopically whorls of atypical squamous cells co-mingle with collagen fibres • Pleomorphic giant/spindle cells may be present • Neoplastic keratinocytes have hyperchromatic eosinophilic cytoplasm, elongated, pleomorphic and veiscular nuclei with multiple nucleoli

  12. Small cell • May resemble metastatic small cell neuroendocrine carcinoma or Merkel cell carcinoma • Invades in cohesive nests with adjacent intense inflammatory and desmoplastic host response • Stains for cytokeratin, but may stain for neuron specific enolase (NSE), a neuroendocrine marker

  13. Verrucous • Exophytic or endophytic masses growing at sites of chronic irritation • Slowly locally invasive, little or no propensity to metastasise • Morphologically appear well differentiated with little atypia • Thickened papillae composed with well differentiated squamous cells invading into dermis

  14. Verrucous • 3 distinct clinicopathologic subtypes • Oral • Associated with tobacco chewing, betel nut chewing, HPV, poor oral hygiene • Typically wart like white/gray lesion • Well differentiated • Plantar • Many crypt like openings • Slowly enlarging, fleshy pink exophytic mass • Verrucous hyper/para keratotic component, epithelial crypts with keratinaceous debris • Buschke-Loewenstein • Anogenital type, described by B-L in 1925 • Occur most commonly in uncircumcised men under 50, associated with HPV 6 & 11 • Present as caulflower like lesions most commonly on glans penis • Extensive verrucous acanthosis with dermal extension, keratinocyte atypia minimal, hypergranulosis and crypt/sinus formation

  15. Keratoacanthoma • Period of rapid growth lasts 4-8 weeks • Potential for spontaneous involution usually within 4-6 months, sometimes with considerable scarring • Clinically tend to be rapid growing smooth, firm nodule with central keratin plug

  16. Histologically difficult to distinguish between benign KA and SCC KA type, so being amalgamated by histopathologists • Atypical squamous proliferation with intradermal invasion • Typically crateriform architecture with keratin plug and well developed collarette

  17. Adenoid / Acantholytic • Form a pseudoglandular appearance • Cells arranged in cords and nests with clefts produced by acantholysis of cells leaving spaces that superficially resemble glands

  18. Enlarged free floating dysplastic keratinocytes found in lumina • Clinically appear as ulcer on head & neck of men in 5th to 6th decade • High incidence of recurrence after radiation therapy • Tend to be more locally aggressive but metastasise less

  19. Bowenoid • Considered to be SCC in situ • Most common site is head and neck, followed by limbs and then trunk • Well demarcated, slow growing, erythematous scaly patch, usually small in size

  20. Histologically shows hyperkeratosis, acanthosis, psoriasiform hyperplasia, full thickness atypia, loss of polarity reflecting cessation of maturation • When neoplastic keratinocytes invade the dermis, this lesion is termed Bowenoid SCC • Especially associated with HPV – HPV2 with extragenital lesions, HPV16 with genital lesions

  21. Metastasis • Overall risk is 2 – 6%, not 0.5% • Recurrent SCC has metastatic rate of 30%, and metastatic cases had a survival rate of 1/3 • Metastases tend to be to regional lymph nodes • Most mets (and local recurrences) are found within first 2 years, and 95% within first 5 years

  22. Risk factors for metastasis and recurrence • Recurrence rate doubled and tripled metastatic rate • Size > 2cm • Grade 3 & 4 vs. Grade 1 & 2 tumours • Well differentiated has recurrence 7%, mod well diff 23%, poor diff 28% • Tumour thickness • 3 year recurrence free survival is 98% for <3.5mm, 84% for > 3.5mm (Breslow thickness) • Rapid growth rate

  23. Sun exposed areas tend to metastasise and recur less than mucosal SCC • Scar SCC are very aggressive • Lip and ear SCC have higher metastatic rate than other head and neck sites (16 & 10%) • Probably due to decreased subcutaneous fat • Nose and scalp, anogenital are intermediate risk • Periungal SCC has high recurrence rate but almost never metastasises • Previous treatment – recurrent cancers have a metastatic rate of 25% • Location – ear 45%, lip 32% metastatic rate

  24. Histopathology • Isolated strands, infiltrative pattern, haphazard growth vs. broad pushing borders • Perineural invasion (occurs in 2-14% SCC, most commonly H&N in elderly men) • Has been quoted as local recurrence 47%, regional mets 35%, distant nodes 15%; so post op RTX commonly offered • NO good evidence that any subtype has greater risk recurrence or metastasis

  25. Immunosuppression • Biologically more aggressive, with higher rates of lymph node metastases and deaths secondary to skin cancer

  26. Tumour size

  27. Tumour depth and metastatic rate

  28. Grades

  29. Surgical Management • Tumours < 2cm diameter are successfully excised 95% of the time with a margin of 4mm, 6mm for high risk cases (Brodland & Zitelli) • Tumours > 2cm diameter require margin of 10mm for equivalent local control rates • Moh’s surgery

  30. Other modalities • Dessication and curettage • Lesions less than 2cm diameter have cure rates of 97-98.8% • Cryosurgery • Well localised, superficial lesions on trunk or limbs • 5FU & Imiquimod & Photodynamic therapy • Useful for actinic keratoses

  31. Radiation Therapy • < 2cm tumours have a cure rate of 95% • Adjunctive RTX must be given within 8 weeks for greatest efficiency • (Late) changes include : • atrophy, fibrosis, hypopigmentation, telangiectasia, ulceration • “As late results of RTX can be poor, it is not recommended for patients under 60 yo with uncomplicated primary SCC” • May hasten natural history of KA

More Related